Company
Headquarters: Carros, France
Employees: 4,907
CEO: Mr. Habib Ramdani
€2.96 Billion
EUR as of Jan. 1, 2026
US$3.48 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| AstraZeneca | $284.38 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Virbac SA manufactures and sells pharmaceutical, biological, nutritional, and diagnostic products for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, and the Middle East and Africa. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. Virbac SA was founded in 1968 and is headquartered in Carros, France.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | €1.43 B |
| EBITDA | €289.8 M |
| Gross Profit TTM | €955.9 M |
| Profit Margin | 9.29% |
| Operating Margin | 17.92% |
| Quarterly Revenue Growth | 5.00% |
Virbac SA has the following listings and related stock indices.
Stock: Euronext: VIRP wb_incandescent
Stock: FSX: V16 wb_incandescent
Stock: OTC: VRBCF wb_incandescent